1
|
Li X, Zhang W, Shu Y, Huo R, Zheng C, Qi Q, Fu P, Sun J, Wang Y, Wang Y, Lu J, Zhao X, Yin G, Wang Q, Hong J. Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells. Sci Rep 2024; 14:15331. [PMID: 38961200 PMCID: PMC11222478 DOI: 10.1038/s41598-024-66290-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2024] [Accepted: 07/01/2024] [Indexed: 07/05/2024] Open
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target to reduce lipids. In 2020, we reported a chimeric camelid-human heavy chain antibody VHH-B11-Fc targeting PCSK9. Recently, it was verified that VHH-B11 binds one linear epitope in the PCSK9 hinge region. To enhance its druggability, we have developed a novel biparatopic B11-H2-Fc Ab herein. Thereinto, surface plasmon resonance (SPR) confirmed the epitope differences in binding-PCSK9 among VHH-B11, VHH-H2 and the approved Repatha. Additionally, SPR revealed the B11-H2-Fc exhibits an avidity of approximately 0.036 nM for PCSK9, representing a considerable increase compared to VHH-B11-Fc (~ 0.69 nM). Moreover, we found the Repatha and B11-H2-Fc exhibited > 95% PCSK9 inhibition efficiency compared to approximately 48% for the VHH-Fc at 7.4 nM (P < 0.0005). Further, we verified its biological activity using the human hepatoma cells G2 model, where the B11-H2-Fc exhibited almost 100% efficiency in PCSK9 inhibition at only 0.75 μM. The immunoblotting results of low-density lipoprotein cholesterol (LDL-c) uptake assay also demonstrated the excellent performance of B11-H2-Fc on recovering the LDL-c receptor (LDLR), as strong as the Repatha (P > 0.05). These findings provide the first evidence of the efficacy of a novel Ab targeting PCSK9 in the field of lipid-lowering drugs.
Collapse
Affiliation(s)
- Xinyang Li
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China.
| | - Wei Zhang
- School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, 518055, Guangdong, China
| | - Yu Shu
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Rui Huo
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Chengyang Zheng
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Qi Qi
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Pengfei Fu
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Jie Sun
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Yuhuan Wang
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Yan Wang
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Juxu Lu
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Xiangjie Zhao
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China
| | - Guoyou Yin
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China.
| | - Qingqing Wang
- Employment and Business Startup Service Center, Henan University of Urban Construction, Ping Dingshan, 467036, China.
| | - Jun Hong
- College of Life Science and Engineering, Henan University of Urban Construction, Ping Dingshan, 467036, China.
| |
Collapse
|
2
|
Patarca R, Haseltine WA. Forty years of HIV research inspires the development of SARS-CoV-2 therapy. J Mol Cell Biol 2024; 15:mjad065. [PMID: 37873695 PMCID: PMC11137671 DOI: 10.1093/jmcb/mjad065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 08/24/2023] [Accepted: 10/20/2023] [Indexed: 10/25/2023] Open
|
3
|
Keri D, Walker M, Singh I, Nishikawa K, Garces F. Next generation of multispecific antibody engineering. Antib Ther 2024; 7:37-52. [PMID: 38235376 PMCID: PMC10791046 DOI: 10.1093/abt/tbad027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 10/16/2023] [Accepted: 11/15/2023] [Indexed: 01/19/2024] Open
Abstract
Multispecific antibodies recognize two or more epitopes located on the same or distinct targets. This added capability through protein design allows these man-made molecules to address unmet medical needs that are no longer possible with single targeting such as with monoclonal antibodies or cytokines alone. However, the approach to the development of these multispecific molecules has been met with numerous road bumps, which suggests that a new workflow for multispecific molecules is required. The investigation of the molecular basis that mediates the successful assembly of the building blocks into non-native quaternary structures will lead to the writing of a playbook for multispecifics. This is a must do if we are to design workflows that we can control and in turn predict success. Here, we reflect on the current state-of-the-art of therapeutic biologics and look at the building blocks, in terms of proteins, and tools that can be used to build the foundations of such a next-generation workflow.
Collapse
Affiliation(s)
- Daniel Keri
- Department of Protein Therapeutics, Research, Gilead Research, 324 Lakeside Dr, Foster City, CA 94404, USA
| | - Matt Walker
- Department of Protein Therapeutics, Research, Gilead Research, 324 Lakeside Dr, Foster City, CA 94404, USA
| | - Isha Singh
- Department of Protein Therapeutics, Research, Gilead Research, 324 Lakeside Dr, Foster City, CA 94404, USA
| | - Kyle Nishikawa
- Department of Protein Therapeutics, Research, Gilead Research, 324 Lakeside Dr, Foster City, CA 94404, USA
| | - Fernando Garces
- Department of Protein Therapeutics, Research, Gilead Research, 324 Lakeside Dr, Foster City, CA 94404, USA
| |
Collapse
|